Stay updated on Lorlatinib in ROS1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Lorlatinib in ROS1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lorlatinib in ROS1+ NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The website has been updated from version v2.13.2 to v2.13.3.
    Difference
    0.3%
    Check dated 2024-12-14T12:25:41.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.
    Difference
    0.3%
    Check dated 2024-12-07T10:39:46.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The website has added new features for data download options and selection fields, while several key government health-related URLs have been removed.
    Difference
    14%
    Check dated 2024-11-23T04:21:29.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Several new government health and information websites have been added, including HHS, NIH, NLM, NCBI, and USA.gov.
    Difference
    0.7%
    Check dated 2024-11-15T22:49:05.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The website has been updated to version v2.12.2, introducing new download options for data in various formats (CSV, JSON, RIS, FHIR) and allowing users to select specific fields for download.
    Difference
    16%
    Check dated 2024-11-08T18:02:32.000Z thumbnail image
  8. Check
    59 days ago
    Change Detected
    Summary
    The website has been updated from version 2.12.0 to 2.12.1.
    Difference
    0.3%
    Check dated 2024-11-01T10:26:50.000Z thumbnail image

Stay in the know with updates to Lorlatinib in ROS1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lorlatinib in ROS1+ NSCLC Clinical Trial page.